Dr. Joel Wiszniak, MD

Dr. Wiszniak practices at Skin and Cancer Associates in Aventura, Florida.

Dr. Wiszniak's NPI, 1861413395, was assigned on July 21, 2006. Dr. Wiszniak graduated from Pierre and Marie Curie University in 1978. Dr. Wiszniak holds Florida license ME53127.

Dr. Wiszniak's primary practice is Skin and Cancer Associates, at 18205 Biscayne Blvd, Aventura, FL 33160 in Miami-Dade County. The practice phone is (954) 473-6750.

Dr. Wiszniak's primary practice is Skin and Cancer Associates in Aventura, Florida. The medical group on file is Skin and Cancer Associates. Dmand AI also links Dr. Wiszniak to 1 more physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wiszniak practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Wiszniak's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Wiszniak is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Wiszniak's licenses on file in 2 states: Florida and Tennessee.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, facial skin infection, itchy rashes, joint cyst and minor head injury among the conditions Dr. Wiszniak treats.

CMS data shows 2,971 Medicare services from Dr. Wiszniak across 17 procedure codes in 2024, for 601 Medicare patients. Medicare paid $145,215 for them. Every service was in an office.

CMS counts 601 Medicare patients who saw Dr. Wiszniak in 2024. The largest group is 75 to 84, with 257 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.10, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wiszniak's median patient age at 72, with 47% women.

In 2024, Dr. Wiszniak wrote 1,224 Medicare Part D claims for 431 patients. 96% of them were for generic drugs. CMS names the drug for 1,112 of them, across 19 drugs with 11 or more claims each, at $27,139 in total drug cost. In 2023, CMS named 974 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Wiszniak for performance year 2024, reported individually. Dr. Wiszniak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 335 procedures of skin biopsy by Dr. Wiszniak, more than 92% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Wiszniak. Dr. Wiszniak's most frequent co-author is Sunil S. Dhawan, MD.

CMS Open Payments shows 170 general payments to Dr. Wiszniak from 31 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $932.

Dmand AI lists 3 awards for Dr. Wiszniak, most recently CMS Stage 1 EHR in 2013.

Dr. Wiszniak graduated from Pierre and Marie Curie University in 1978. Dr. Wiszniak is a member of AAD.

Dr. Wiszniak is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.